Please assess the completion status of the following clinical trial:

Trial Title: Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Undergone allogeneic cell transplantation ≥21 days prior to dosing~* Meet one of the below criteria:~  1. AdV viremia DNA ≥10,000 copies/mL, OR~ 2. AdV viremia DNA results of ≥1,000 copies/mL, AND~     1. has absolute lymphocyte count \<180/mm3, OR~    2. has received T cell depletion OR~    3. had a cord blood transplant.~Exclusion Criteria:~* Grade 3 or higher acute GVHD~* Ongoing therapy with high-dose systemic corticosteroids~* Uncontrolled viral (other than AdV), bacterial, or fungal infection(s)~* Pregnant or lactating female unwilling to discontinue nursing prior to randomization~* History of severe prior reactions to blood product transfusions~NOTE: Other protocol-defined inclusion/exclusion criterion may apply.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Posoleucel + SoC (Type: EXPERIMENTAL): Posoleucel + SOC; then placebo + SOC for patients who meet optional protocol-defined crossover criteria
- Placebo + SoC (Type: PLACEBO_COMPARATOR): Placebo + SOC; then Posoleucel + SOC for patients who meet optional protocol-defined crossover criteria

Based on this trial design, predict the completion outcome and termination type (if applicable).